Atrium Therapeutics, Inc.
corporate_fare Company Profile
Atrium Therapeutics, Inc. (NASDAQ:RNA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for RNA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-07-14, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for RNA spans 8-K, 10-Q, 10-K, DEFA14A.
Recent high-impact activity:
- FDA Clears Atrium's IND for ATR 1072, Phase 1/2 Trial to Start
- FDA Clears Atrium Therapeutics to Launch First Clinical Trial for Rare Heart Disease
- Atrium Therapeutics Reports Strong Q1 Cash Position of $267.8M, $19.6M Collaboration Revenue Post-Spin-Off
- Atrium Therapeutics Reports First Q1 Results as Independent Company with Strong Cash Position and $15M Milestone
- Atrium Therapeutics Reports Strong Q1 with $15M BMS Milestone and $268M Cash
Short Interest & Short Volume
8.15 days to coverFINRA reported short interest of 3,397,791 shares in RNA as of the September 15, 2026 settlement, a 1.4% increase from the prior period — about 8.2 days to cover at its recent average daily volume. On October 2, 2026, 40.1% of RNA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.